

**Serious adverse events of special interest following  
mRNA vaccination in randomized trials**

Joseph Fraiman, MD<sup>1</sup>  
Juan Erviti, PharmD, PhD<sup>2</sup>  
Mark Jones, PhD<sup>3</sup>  
Sander Greenland, MA, MS, DrPH, C Stat<sup>4</sup>  
Patrick Whelan, MD PhD<sup>5</sup>  
Robert M. Kaplan, PhD<sup>6</sup>  
Peter Doshi, PhD<sup>7</sup>

**Affiliations**

- <sup>1</sup> Louisiana State University, Lallie Kemp Regional Medical Center, Independence, LA  
<sup>2</sup> Unit of Innovation and Organization. Navarre Health Service, Spain  
<sup>3</sup> Institute of Evidence-Based Healthcare, Bond University, Gold Coast, QLD, Australia  
<sup>4</sup> Fielding School of Public Health, University of California, Los Angeles  
<sup>5</sup> University of California, Los Angeles  
<sup>6</sup> School of Medicine, Stanford University  
<sup>7</sup> University of Maryland School of Pharmacy, Baltimore, MD

**Correspondence to:** Peter Doshi, 220 N Arch Street, Baltimore, MD, 21201  
pdoshi@rx.umaryland.edu



26 **ABSTRACT**

27

28 **Introduction.** In 2020, prior to COVID-19 vaccine rollout, the Coalition for Epidemic  
29 Preparedness Innovations and Brighton Collaboration created a priority list, endorsed by the  
30 World Health Organization, of potential adverse events relevant to COVID-19 vaccines. We  
31 leveraged the Brighton Collaboration list to evaluate serious adverse events of special interest  
32 observed in phase III randomized trials of mRNA COVID-19 vaccines.

33

34 **Methods.** Secondary analysis of serious adverse events reported in the placebo-controlled,  
35 phase III randomized clinical trials of Pfizer and Moderna mRNA COVID-19 vaccines  
36 (NCT04368728 and NCT04470427), focusing analysis on potential adverse events of special  
37 interest identified by the Brighton Collaboration.

38

39 **Results.** Pfizer and Moderna mRNA COVID-19 vaccines were associated with an increased  
40 risk of serious adverse events of special interest, with an absolute risk increase of 10.1 and 15.1  
41 per 10,000 vaccinated over placebo baselines of 17.6 and 42.2 (95% CI -0.4 to 20.6 and -3.6 to  
42 33.8), respectively. Combined, the mRNA vaccines were associated with an absolute risk  
43 increase of serious adverse events of special interest of 12.5 per 10,000 (95% CI 2.1 to 22.9).  
44 The excess risk of serious adverse events of special interest surpassed the risk reduction for  
45 COVID-19 hospitalization relative to the placebo group in both Pfizer and Moderna trials (2.3  
46 and 6.4 per 10,000 participants, respectively).

47

48 **Discussion.** The excess risk of serious adverse events found in our study points to the need for  
49 formal harm-benefit analyses, particularly those that are stratified according to risk of serious  
50 COVID-19 outcomes such as hospitalization or death.

51

52 **Funding.** This study had no funding support.

53

54 **Keywords:** SARS-CoV-2; COVID-19; vaccines; COVID-19 vaccines; mRNA vaccines; Pfizer-  
55 BioNTech COVID-19 vaccine BNT162b2; Moderna COVID-19 vaccine mRNA-1273;  
56 NCT04368728; NCT04470427; serious adverse events; adverse events of special interest;  
57 Brighton Collaboration; Coalition for Epidemic Preparedness Innovations; Safety Platform for  
58 Emergency vACcines

59

60 **Conflicts of interest:**

61 **JF, JE, MJ, SG, PW, RK:** none to declare. **PD** has received travel funds from the European  
62 Respiratory Society (2012) and Uppsala Monitoring Center (2018); grants from the FDA  
63 (through University of Maryland M-CERSI; 2020), Laura and John Arnold Foundation (2017-22),  
64 American Association of Colleges of Pharmacy (2015), Patient-Centered Outcomes Research  
65 Institute (2014-16), Cochrane Methods Innovations Fund (2016-18), and UK National Institute  
66 for Health Research (2011-14); was an unpaid IMEDS steering committee member at the  
67 Reagan-Udall Foundation for the FDA (2016-2020) and is an editor at The BMJ. The views  
68 expressed here are those of the authors and do not necessarily reflect those of their employers.

69

## 70 INTRODUCTION

71  
72 In March 2020, the Brighton Collaboration and the Coalition for Epidemic Preparedness  
73 Innovations partnership, Safety Platform for Emergency vACcines (SPEAC), created and  
74 subsequently updated a “priority list of potential adverse events of special interest relevant to  
75 COVID-19 vaccine trials.”<sup>1</sup> The list comprises adverse events of special interest (AESIs) based  
76 on the specific vaccine platform, adverse events associated with prior vaccines in general,  
77 theoretical associations based on animal models, and COVID-19 specific  
78 immunopathogenesis.<sup>1</sup> The World Health Organization’s Global Advisory Committee on  
79 Vaccine Safety endorsed and recommended the reporting of AESIs based on this priority list. To  
80 our knowledge, however, the list has not been applied to serious adverse events in randomized  
81 trial data.

82  
83 We sought to investigate the association between FDA-authorized mRNA COVID-19 vaccines  
84 and serious adverse events identified by the Brighton Collaboration, using data from the phase  
85 III randomized, placebo-controlled clinical trials on which authorization was based. We then use  
86 the results to illustrate the need for formal harm-benefit analyses of the vaccines that are  
87 stratified according to risk of serious COVID-19 outcomes, as well as contextualize the findings  
88 against post-authorization observational data.

## 89 METHODS

90  
91  
92 Pfizer and Moderna each submitted the results of one phase III randomized trial in support of  
93 the FDA’s emergency use authorization of their vaccines. Two methodologist reviewers  
94 searched journal publications and trial data on the FDA’s and Health Canada’s websites to  
95 locate serious adverse event results tables for these trials. The Pfizer and Moderna trials are  
96 expected to follow participants for two years. Within weeks of the emergency authorization,  
97 however, the sponsors began a process of unblinding all participants who elected to be  
98 unblinded. In addition, those who received placebo were offered the vaccine. These self-  
99 selection processes may have introduced nonrandom differences between the vaccine and  
100 unvaccinated participants, thus rendering the post-authorization data less reliable. Therefore, to  
101 preserve randomization, we used the interim datasets that were the basis for emergency  
102 authorization in December 2020, approximately 4 months after trials commenced.

103  
104 The definition of a serious adverse event (SAE) was provided in each trial’s study protocol and  
105 included in the supplemental material of the trial’s publication.<sup>2-4</sup> Pfizer and Moderna used  
106 nearly identical definitions, consistent with regulatory expectations. An SAE was defined as an  
107 adverse event that results in any of the following conditions: death; life-threatening at the time of  
108 the event; inpatient hospitalization or prolongation of existing hospitalization; persistent or  
109 significant disability/incapacity; a congenital anomaly/birth defect; medically important event,  
110 based on medical judgment.

111  
112 In addition to journal publications, we searched the websites of the FDA (for advisory committee  
113 meeting materials) and Health Canada (for sections of the dossier submitted by sponsors to the

114 regulator).<sup>5</sup> For the FDA website, we considered presentations by both the FDA and the  
115 sponsors.<sup>6</sup> Within each of these sources, we searched for SAE results tables that presented  
116 information by specific SAE type; we chose the most recent SAE table corresponding to the  
117 FDA's requirement for a safety median follow-up time of at least 2 months after dose 2.

118  
119 For each trial, blinded SAE tables (containing SAE types without results data) were prepared.  
120 Using the blinded SAE tables, two clinician reviewers (JF and JE) independently judged whether  
121 each SAE type was an AESI.

122  
123 Our project used an AESI list derived from the work of Brighton Collaboration's Safety Platform  
124 for Emergency vACCines (SPEAC) Project. This effort created an AESI list which categorizes  
125 AESIs into three categories: those included because they are seen with COVID-19, those with a  
126 proven or theoretical association with vaccines in general, and those with proven or theoretical  
127 associations with specific vaccine platforms. The first version was produced in March 2020  
128 based on experience from China. Following the second update (May 2020), the WHO Global  
129 Advisory Committee on Vaccine Safety (GACVS) adopted the list, and Brighton commenced a  
130 systematic review process "to ensure an ongoing understanding of the full spectrum of COVID-  
131 19 disease and modification of the AESI list accordingly."<sup>7</sup> This resulted in three additional  
132 AESIs being added to the list in December 2020. The subsequent (and most recent fourth)  
133 update did not result in any additional AESIs being added to the list.

134  
135 We matched SAEs recorded in the trial against an expanded list of AESIs created by combining  
136 Brighton's SPEAC COVID-19 AESI list with a list of 29 clinical diagnoses Brighton identified as  
137 "known to have been reported but not in sufficient numbers to merit inclusion on the AESI list."<sup>7</sup>  
138 Sensitivity analysis was used to determine whether the original versus expanded list had an  
139 effect on identifying a safety concern. For SAEs that described symptoms, not diagnoses, the  
140 clinician reviewers independently judged whether each SAE type was likely to have been  
141 caused by an AESI. For example, the SAE "abdominal pain" is a symptom based diagnosis,  
142 which was judged as fitting within the SPEAC clinical diagnosis of "colitis/enteritis."  
143 Disagreements were resolved through consensus; in two cases, consensus could not be  
144 reached and were resolved by the judgment of a third clinician reviewer (PW) to create a  
145 majority opinion. For each included SAE, we recorded the corresponding Brighton  
146 Collaboration AESI category and organ system.

147  
148 Risk ratios and risk differences between vaccine and placebo groups were calculated for the  
149 incidence of SAEs. We excluded SAEs that were efficacy outcomes (i.e. COVID-19). Because  
150 we did not have access to individual participant data, to account for the occasional multiple  
151 SAEs within single participants, we reduced the effective sample size by multiplying standard  
152 errors in the combined SAE analyses by the square root of the ratio of the number of SAEs to  
153 the number of patients with an SAE. This adjustment increased standard errors by 10% (Pfizer)  
154 and 18% (Moderna), thus expanding the interval estimates. We estimated combined risk ratios  
155 and risk differences for the two mRNA vaccines by averaging over the risks using logistic  
156 regression models.

157

158 We used a simple harm-benefit framework to place our results in context. The analysis  
159 compared risks of excess serious AESIs against reductions in serious complications of COVID-  
160 19.

161

162

## 163 **RESULTS**

164

165 Serious adverse event tables were located for each of the vaccine trials submitted for EUA in  
166 the United States: Pfizer-BioNTech COVID-19 vaccine BNT162b2 (NCT04368728)<sup>2,8,9</sup> and  
167 Moderna COVID-19 vaccine mRNA-1273 (NCT04470427).<sup>3,10,11</sup> (**Table 1**)

168

### 169 ***Reporting windows and all-cause serious adverse events***

170

171 Moderna reported SAEs from dose 1 whereas Pfizer limited reporting from dose 1 to 1 month  
172 after dose 2. Both studies reported all data at the time of data cutoff.

173

174 The Pfizer trial reported a 36% higher risk of serious adverse events unrelated to COVID-19 in  
175 vaccinated participants than placebo recipients: 67.5 per 10,000 versus 49.5 per 10,000; risk  
176 ratio 1.36 (95% compatibility<sup>1</sup> interval, CI 1.02 to 1.83). The Moderna trial reported a 5% higher  
177 risk of SAEs unrelated to COVID-19 in vaccinated individuals compared to those receiving  
178 placebo: 136 per 10,000 versus 129 per 10,000; risk ratio 1.05 (95% CI 0.83 to 1.32).

179 Combined, there was a 15% higher risk of SAEs unrelated to COVID-19 in mRNA vaccine  
180 recipients than placebo recipients: 98 per 10,000 versus 85 per 10,000; risk ratio 1.15 (95% CI  
181 0.96 to 1.38). (**Table 2**)

182

### 183 ***Serious adverse events of special interest***

184

185 Regarding whether each SAE type was included on the SPEAC derived AESI list, agreement  
186 between the two independent clinician reviewers was 86% (281/325); 40 of the 44  
187 disagreements were resolved through consensus, and only four disagreements necessitated a  
188 third clinician reviewer. **Supplemental Table 1** includes a full list of included and excluded  
189 SAEs across both trials.

190

191 In the Pfizer trial, 52 serious AESI (27.7 per 10,000) were reported in the vaccine group and 33  
192 (17.6 per 10,000) in the placebo group. This difference corresponds to a 57% increased risk of  
193 serious AESI (RR 1.57 95% CI 0.98 to 2.54) and an absolute risk increase of 10.1 serious AESI  
194 per 10,000 vaccinated participants (95% CI -0.4 to 20.6). In the Moderna trial, 87 serious AESI  
195 (57.3 per 10,000) were reported in the vaccine group and 64 (42.2 per 10,000) in the placebo  
196 group. This difference corresponds to a 36% increased risk of serious AESI (RR 1.36 95% CI  
197 0.93 to 1.99) and an absolute risk increase of 15.1 serious AESI per 10,000 vaccinated  
198 participants (95% CI -3.6 to 33.8). Combining the trials, there was a 43% increased risk of

---

<sup>1</sup> A compatibility interval is identical to a confidence interval, but relabeled to emphasize that it is not a Bayesian posterior interval (as is improperly suggested by the “confidence” label).<sup>12,13</sup>

199 serious AESI (RR 1.43; 95% CI 1.07 to 1.92) and an absolute risk increase of 12.5 serious AESI  
200 per 10,000 vaccinated participants (95% CI 2.1 to 22.9). **(Table 2)**

201  
202 Of the 236 serious AESIs occurring across the Pfizer and Moderna trials, 97% (230/236) were  
203 adverse event types included as AESIs because they are seen with COVID-19. In both Pfizer  
204 and Moderna trials, the largest increase in absolute risk occurred amongst the Brighton  
205 category of coagulation disorders. Cardiac disorders have been of central concern for mRNA  
206 vaccines; more cardiovascular AESIs occurred in the vaccine group in the Pfizer trial, but  
207 cardiovascular AESI events were balanced in the Moderna trial. **(Tables 3 and 4)**

208

### 209 ***Sensitivity analysis***

210

211 In a sensitivity analysis, we restricted the serious AESI analysis to those AESIs listed in  
212 SPEAC's COVID-19 AESI list (i.e. separating out Brighton's list of 29 clinical diagnoses "known  
213 to have been reported but not in sufficient numbers to merit inclusion on the AESI list.") This  
214 reduced the total number of AESIs across the two trials by 48 (35 vaccine group, 13 placebo  
215 group). There was still a higher risk of serious AESI when limited to the SPEAC COVID-19 AESI  
216 list, but the magnitude of the increase (in both relative and absolute terms) was smaller than  
217 when using the larger AESI list. **(Supplemental Table 2).**

218

### 219 ***Harm-benefit considerations***

220

221 In the Moderna trial, the excess risk of serious AESIs (15.1 per 10,000 participants) surpassed  
222 the risk reduction for COVID-19 hospitalization relative to the placebo group (6.4 per 10,000  
223 participants).<sup>3</sup> In the Pfizer trial, the excess risk of serious AESIs (10.1 per 10,000) surpassed  
224 the risk reduction for COVID-19 hospitalization relative to the placebo group (2.3 per 10,000  
225 participants).

226

### 227 ***Comparison with FDA reviews and post-authorization studies***

228

229 In their review of SAEs that supported the authorization of the Pfizer and Moderna vaccines, the  
230 FDA concluded that SAEs were, for Pfizer, "balanced between treatment groups,"<sup>14</sup> and for  
231 Moderna, were "without meaningful imbalances between study arms."<sup>15</sup> In contrast to the FDA  
232 analysis, we found an increased risk of all cause SAEs in the Pfizer trial. While our analysis  
233 excluded SAEs related to COVID-19 (because it is an efficacy outcome), this exclusion did not  
234 explain the difference given the low risk of SAEs attributed to COVID-19 (0 in the vaccine arm, 1  
235 in the placebo arm). Instead, the difference in findings may in part be explained by the fact that  
236 the FDA analyzed the total number of participants experiencing any SAE, whereas our analysis  
237 was based on the total number of SAE events. Given that approximately twice as many  
238 individuals in the vaccine group experienced multiple SAEs than the placebo group (there were  
239 24 more events than participants in the vaccine group, compared to 13 in the placebo group),  
240 FDA's analysis of only the incidence of participants experiencing any SAE would not reflect the  
241 observed increase in multiple SAEs in the vaccine group.

242

243 A more important factor, however, may be that FDA's review of non-fatal SAEs used a different  
244 analysis population with different follow-up windows. The FDA reported 126 of 21621 (0.6%) of  
245 vaccinated participants experienced at least one SAE at data cutoff compared to 111 of 21631  
246 (0.5%) of placebo participants. In contrast, our analysis found 127 SAEs among 18,801 vaccine  
247 recipients versus 93 SAEs among 18,785 placebo recipients.<sup>14</sup> While summary results for the  
248 population we analyzed was provided in a table, FDA did not report an analysis of them. The  
249 substantially larger denominators in FDA's analysis (5,666 more participants) reflect the fact that  
250 their analysis included all individuals receiving at least one dose (minus 196 HIV-positive  
251 participants), irrespective of the duration of post-injection follow-up time. In contrast, our  
252 analysis was based on the study population with median follow-up  $\geq 2$  months after dose 2  
253 (minus 120 HIV-positive participants), of which 98.1% had received both doses.<sup>2,16</sup> The FDA's  
254 analysis of SAEs thus included thousands of additional participants with very little follow-up, of  
255 which the large majority had only received 1 dose.

256  
257 Although the randomized trials offer high level evidence for a causal association, the sparsity of  
258 their data necessitates that harm-benefit analyses also consider observational data. Since their  
259 emergency authorization in December 2020, hundreds of millions of doses of Pfizer and  
260 Moderna COVID-19 vaccines have been administered and post-authorization observational  
261 data offer a complementary opportunity to study AESIs. Post-authorization observational safety  
262 studies include cohort studies (which make use of medical claims or electronic health records)  
263 and disproportionality analyses (which leverage spontaneous adverse event reporting systems).  
264 In July 2021, the FDA reported detecting four potential adverse events of interest: pulmonary  
265 embolism, acute myocardial infarction, immune thrombocytopenia, and disseminated  
266 intravascular coagulation following Pfizer's vaccine based on medical claims data in older  
267 Americans.<sup>17</sup> Three of these four serious adverse event types would be categorized as  
268 coagulation disorders, which is the Brighton AESI category which showed the largest absolute  
269 increase in the vaccine group in both the Pfizer and Moderna trials. FDA stated it would further  
270 investigate the findings but at the time of our writing has not issued an update. Similarly,  
271 spontaneous-reporting systems have registered serious adverse reactions including  
272 anaphylaxis (all COVID-19 vaccines), thrombocytopenia syndrome among premenopausal  
273 females (Janssen vaccine), and myocarditis and pericarditis among younger males (Pfizer and  
274 Moderna vaccines).<sup>18,19</sup>

275  
276 Using data from three postmarketing safety databases for vaccines (VAERS, EudraVigilance,  
277 and VigiBase), disproportionality studies have reported an increase in many of the same SAE  
278 types found in the present study.<sup>20-22</sup> For example, a study using VAERS and EudraVigilance  
279 comparing the disproportionality of adverse event reports between the influenza vaccine versus  
280 the mRNA COVID-19 vaccines reported increased relative risk of the following Brighton AESIs:  
281 cardiovascular events, coagulation events, hemorrhages, gastrointestinal events, and  
282 thromboses. While CDC published a protocol<sup>23</sup> in early 2021 for using proportional reporting  
283 ratios for signal detection in the VAERS database, the agency has not yet reported such a  
284 study.<sup>24</sup> Among self-controlled case series, one reported an incidence rate ratio of 1.38 (95% CI  
285 1.12-1.71) for hemorrhagic stroke following Pfizer vaccine,<sup>25</sup> another reported 0.97 (95% CI  
286 0.81-1.15),<sup>26</sup> while a cohort study<sup>27</sup> reported 0.84 (95% CI 0.54-1.27).



287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330

## DISCUSSION

Using a prespecified list of AESI identified by the Brighton Collaboration, an increase in serious AESI was found in the mRNA COVID-19 vaccine group in both the Pfizer and Moderna adult phase III trials, from 10.1 (Pfizer) to 15.1 (Moderna) additional events for every 10,000 individuals vaccinated.

Comparing the excess of serious AESI against the reduction of serious complications of COVID-19 among the vaccinated is essential for harm-benefit analyses. The results show an excess risk of serious AESIs greater than the reduction in COVID-19 hospitalizations in both Pfizer and Moderna trials. These results are compatible with a recent preprint analysis of COVID-19 vaccine trials by Benn et al., which found no evidence of a reduction in overall mortality in the mRNA vaccine trials based on data from the later, March 2021 BLA (Biologics License Application) timepoints that underpinned subsequent regulatory approval (31 deaths in the vaccine arms versus 30 events in the placebo arms; RR 1.03, 95% CI 0.63 to 1.71).<sup>28</sup> Our analysis as well as Benn et al. point to the need for formal harm-benefit analyses especially in individuals at low risk of COVID-19 hospitalization or death. Using VAERS data, Krug et al. attempted such an analysis, albeit focused on just one SAE (myocarditis)<sup>19</sup> Individual participant data for all SAEs is not publicly available at present, but would help identify factors (e.g. age and comorbidities) that may elevate the risk of serious AESIs. It would also be essential to compare long-term outcomes of vaccinated and unvaccinated groups, e.g., for symptoms identified with “long covid.”

Adverse events detected in the post-marketing period have led to the withdrawal of several past vaccines. An example is intussusception following one brand of rotavirus vaccine: around 1 million children were vaccinated before identification of intussusception, which occurred in around 1 per 10,000 vaccinees.<sup>29</sup> Despite the unprecedented scale of COVID-19 vaccine administration, the AESI types identified in our study may still be challenging to detect with observational methods. Most cohort study designs crucially depend upon comparing the risks of adverse events “observed” against a background (or “expected”) risk. However, background incidence risks display great variation, by database, age group, and sex.<sup>30</sup> If the risk ratio of 1.4 estimated in our analysis were the actual effect size, it could be quite difficult to unambiguously replicate it with observational data given concerns about systematic as well as random errors.<sup>31-</sup>

<sup>33</sup>

In addition, disproportionality analyses following COVID-19 vaccination also have limitations, particularly with respect to the type of adverse events seen in our study. The majority of SAE types that contributed to our results are relatively common events, such as ischemic stroke, acute coronary syndrome, and brain hemorrhage. This complicates signal detection because clinical suspicion of an adverse vaccine reaction following an event commonly seen in clinical practice will be lower than for less commonly observed SAEs like myocarditis. For this reason, the basic ingredient for effective pharmacovigilance--clinical suspicion leading to the filing of an individual case safety report--may be far less common in the post-authorization setting. At the

331 same time, heightened awareness about COVID-19 vaccines can result in over- and under-  
332 reporting. Public health messages assuring vaccine safety may lower clinical suspicion of  
333 potential causal relationships, whereas messages about potential harms can conversely  
334 stimulate reports that otherwise may not have been made. There are thus factors that can lead  
335 to bias in either direction, further complicating analysis and interpretation. In contrast to these  
336 problems, in the randomized clinical trials used in this analysis, all SAEs were to be recorded,  
337 irrespective of clinical judgment regarding potential causality.

338  
339 Although our analysis is secondary, reanalyses of clinical trial data have led to the detection of  
340 adverse events well after the market entry of major drugs such as rofecoxib and  
341 rosiglitazone.<sup>34,35</sup> Our analysis has an advantage over postmarketing observational studies in  
342 that the data are from blinded, placebo-controlled randomized trials vetted by the FDA, and  
343 uses the Brighton Collaboration AESI list, which was pre-specified, endorsed by WHO, and  
344 established well before the availability of the clinical-trial results, and designed for use in  
345 COVID-19 vaccine trials.

346  
347 Limitations of our study include that Pfizer's SAE table did not include SAEs occurring past 1  
348 month after dose 2. This reporting threshold may have led to an undercounting of serious AESIs  
349 in the Pfizer study, and for both studies, the limited follow up time prevented an analysis of  
350 harm-benefit over a longer time period. It should also be recognized that all SAEs in our  
351 analysis are those that met the regulatory definition of a serious adverse event. However, many  
352 adverse event types which a patient may themselves judge as serious may not meet this  
353 regulatory threshold.

354  
355 Another limitation is our lack of access to individual participant data, which forced us to use a  
356 conservative adjustment to the standard errors. The 95% CI<sup>12,13</sup> calculated are therefore only  
357 approximate because we do not know which patients had multiple events. Furthermore, despite  
358 our attempt to remove efficacy endpoints from our analysis (i.e., SAEs labeled as COVID-19,  
359 COVID-19 pneumonia, and "SARS-CoV-2 test positive"), it was not possible to identify and  
360 remove SAEs that occurred in patients with serious complications of COVID-19 (e.g., acute  
361 respiratory failure, cardiac arrest, and acute kidney injury), which are common. Of 18 total  
362 efficacy SAEs removed from our analysis, 17 were in the Moderna trial, and of these, 16 were in  
363 the placebo arm. This suggests the possibility that SAEs were overcounted in the placebo arm  
364 of our analyses, primarily for Moderna's vaccine, due to our inability to remove COVID-19-  
365 related SAEs. These study limitations all stem from the fact that the raw data from COVID-19  
366 vaccine clinical trials are not publicly available.<sup>36,37</sup> Given the global public health implications,  
367 there is an urgency to make all COVID-19 trial data public, particularly regarding serious  
368 adverse events, without any further delay.

369  
370 Finally, we emphasize that the elevated risk of serious AESIs in the vaccine group represents  
371 an average across the group. SAEs may not be distributed equally across the demographic  
372 subgroups enrolled in the trial, and the risks may be substantially less in some groups  
373 compared to others. Thus, knowing the actual demographics of those who experienced an  
374 increase in serious AESI in the vaccine group is necessary for a proper harm-benefit analysis.

375 A systematic review and meta-analysis using individual participant data should be undertaken to  
376 address questions of harm-benefit in various demographic subgroups. Full transparency of the  
377 COVID-19 vaccine clinical trial data is needed to properly evaluate these questions.  
378 Unfortunately, well over a year after widespread use of COVID-19 vaccines, participant level  
379 data remain inaccessible.<sup>36,37</sup>

380  
381

382 **Author Contributions:** All authors had full access to all of the data in the study (available at  
383 <https://doi.org/10.5281/zenodo.6564403>), and take responsibility for the integrity of the data and  
384 the accuracy of the data analysis.

385

386 Study concept and design: All authors

387 Acquisition of data: Doshi

388 Analysis and interpretation: All authors

389 Statistical analysis: Jones, Greenland

390 Drafting of the manuscript: Fraiman, Doshi

391 Critical revision of the manuscript for important intellectual content: All authors

392

393 **Acknowledgements:** We thank Jean Rees for help identifying sources of data.

394

395 **Funding:** This study had no funding support.

396

397 **Conflicts of interest:**

398 **JF, JE, MJ, SG, PW, RK:** none to declare. **PD** has received travel funds from the European  
399 Respiratory Society (2012) and Uppsala Monitoring Center (2018); grants from the FDA  
400 (through University of Maryland M-CERSI; 2020), Laura and John Arnold Foundation (2017-22),  
401 American Association of Colleges of Pharmacy (2015), Patient-Centered Outcomes Research  
402 Institute (2014-16), Cochrane Methods Innovations Fund (2016-18), and UK National Institute  
403 for Health Research (2011-14); was an unpaid IMEDS steering committee member at the  
404 Reagan-Udall Foundation for the FDA (2016-2020) and is an editor at The BMJ. The views  
405 expressed here are those of the authors and do not necessarily reflect those of their employers.

406

407 **References:**

- 408 1. Law B, Pim C. SO2-D2.1.3 Priority List of COVID-19 Adverse events of special interest  
409 [Internet]. 2021 Oct [cited 2022 Feb 17]. Available from: [https://brightoncollaboration.us/wp-](https://brightoncollaboration.us/wp-content/uploads/2021/11/SO2_D2.1.3_COVID-19_AESI-update_V1.0_Part-2_09Nov2021.pdf)  
410 [content/uploads/2021/11/SO2\\_D2.1.3\\_COVID-19\\_AESI-update\\_V1.0\\_Part-](https://brightoncollaboration.us/wp-content/uploads/2021/11/SO2_D2.1.3_COVID-19_AESI-update_V1.0_Part-2_09Nov2021.pdf)  
411 [2\\_09Nov2021.pdf](https://brightoncollaboration.us/wp-content/uploads/2021/11/SO2_D2.1.3_COVID-19_AESI-update_V1.0_Part-2_09Nov2021.pdf)
- 412 2. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and  
413 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med [Internet]. 2020 Dec  
414 31;383(27):2603–15. Available from: <http://dx.doi.org/10.1056/NEJMoa2034577>
- 415 3. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of  
416 the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med [Internet]. 2021 Feb 4;384(5):403–  
417 16. Available from: <http://dx.doi.org/10.1056/NEJMoa2035389>

- 418 4. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and  
419 Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med* [Internet].  
420 2021 Jun 10;384(23):2187–201. Available from: <http://dx.doi.org/10.1056/NEJMoa2101544>
- 421 5. Health Canada. Search for clinical information on drugs and medical devices [Internet].  
422 2019 [cited 2021 Nov 9]. Available from: <https://clinical-information.canada.ca/>
- 423 6. Food and Drug Administration. Meeting Materials, Vaccines and Related Biological  
424 Products Advisory Committee [Internet]. U.S. Food and Drug Administration. 2022 [cited  
425 2022 Feb 18]. Available from: [https://www.fda.gov/advisory-committees/vaccines-and-  
426 related-biological-products-advisory-committee/meeting-materials-vaccines-and-related-  
427 biological-products-advisory-committee](https://www.fda.gov/advisory-committees/vaccines-and-related-biological-products-advisory-committee/meeting-materials-vaccines-and-related-biological-products-advisory-committee)
- 428 7. Law B. SO2-D2.1.2 Priority List of COVID-19 Adverse events of special interest: Quarterly  
429 update December 2020 [Internet]. 2020 Dec [cited 2020 Dec 20]. Available from:  
430 [https://brightoncollaboration.us/wp-content/uploads/2021/01/SO2\\_D2.1.2\\_COVID-  
431 19\\_AESI-update-23Dec2020-review\\_final.pdf](https://brightoncollaboration.us/wp-content/uploads/2021/01/SO2_D2.1.2_V1.2_COVID-19_AESI-update-23Dec2020-review_final.pdf)
- 432 8. Pfizer-BioNTech. PFIZER-BIONTECH COVID-19 VACCINE (BNT162, PF-07302048)  
433 VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE  
434 BRIEFING DOCUMENT. [cited 2021 Dec 20]; Available from:  
435 <https://www.fda.gov/media/144246/download#page=87>
- 436 9. Pfizer. Final Analysis Interim Report: A Phase 1/2/3, Placebo-Controlled, Randomized,  
437 Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity,  
438 and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy  
439 Individuals (Protocol C4591001) [Internet]. [cited 2022 May 3]. Available from:  
440 <https://clinical-information.canada.ca/ci-rc/item/244906>; [https://clinical-  
441 information.canada.ca/ci-rc-vu.pdf?file=m5/c45/c4591001-fa-interim-report-  
442 body\\_Unblinded\\_Redacted.pdf&id=244906](https://clinical-information.canada.ca/ci-rc-vu.pdf?file=m5/c45/c4591001-fa-interim-report-body_Unblinded_Redacted.pdf&id=244906)
- 443 10. Moderna. Sponsor briefing document [Internet]. 2020 Dec [cited 2022 Feb 21]. Available  
444 from: <https://www.fda.gov/media/144452/download>
- 445 11. Moderna. Unblinded Safety Tables Batch 1 (DS2) [Internet]. [cited 2022 May 3]. Available  
446 from: <https://clinical-information.canada.ca/ci-rc/item/244946>; [https://clinical-  
447 information.canada.ca/ci-rc-vu.pdf?file=m5/5.3.5.1/m5351-mrna-1273-p301-p-unblinded-  
448 safety-tables-batch-1.pdf&id=244946](https://clinical-information.canada.ca/ci-rc-vu.pdf?file=m5/5.3.5.1/m5351-mrna-1273-p301-p-unblinded-safety-tables-batch-1.pdf&id=244946)
- 449 12. Amrhein V, Greenland S, McShane B. Scientists rise up against statistical significance.  
450 *Nature* [Internet]. 2019 Mar;567(7748):305–7. Available from:  
451 <http://dx.doi.org/10.1038/d41586-019-00857-9>
- 452 13. Rafi Z, Greenland S. Semantic and cognitive tools to aid statistical science: replace  
453 confidence and significance by compatibility and surprise. *BMC Med Res Methodol*  
454 [Internet]. 2020 Sep 30;20(1):244. Available from: [http://dx.doi.org/10.1186/s12874-020-  
455 01105-9](http://dx.doi.org/10.1186/s12874-020-01105-9)
- 456 14. Food and Drug Administration. Emergency Use Authorization for Pfizer-BioNTech COVID-  
457 19 Vaccine Review Memo [Internet]. 2020 Dec [cited 2022 Feb 21]. Available from:  
458 <https://www.fda.gov/media/144416/download>

- 459 15. Food and Drug Administration. Moderna COVID-19 Vaccine EUA FDA review  
460 memorandum [Internet]. 2020 Dec [cited 2022 Feb 21]. Available from:  
461 <https://www.fda.gov/media/144673/download>
- 462 16. Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine EUA review  
463 memorandum [Internet]. 2020 Dec [cited 2022 Mar 30]. Available from:  
464 <https://www.fda.gov/media/144416/download>
- 465 17. Food and Drug Administration. Initial Results of Near Real-Time Safety Monitoring COVID-  
466 19 Vaccines [Internet]. 2021 [cited 2022 Mar 30]. Available from:  
467 [https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/initial-results-near-](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/initial-results-near-real-time-safety-monitoring-covid-19-vaccines-persons-aged-65-years-and-older)  
468 [real-time-safety-monitoring-covid-19-vaccines-persons-aged-65-years-and-older](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/initial-results-near-real-time-safety-monitoring-covid-19-vaccines-persons-aged-65-years-and-older)
- 469 18. CDC. Selected adverse events reported after COVID-19 vaccination [Internet]. 2021 [cited  
470 2021 May 28]. Available from: [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html)  
471 [ncov/vaccines/safety/adverse-events.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html)
- 472 19. Krug A, Stevenson J, Høeg TB. BNT162b2 Vaccine-Associated Myo/Pericarditis in  
473 Adolescents: A Stratified Risk-Benefit Analysis. *Eur J Clin Invest* [Internet]. 2022  
474 May;52(5):e13759. Available from: <http://dx.doi.org/10.1111/eci.13759>
- 475 20. Dutta S, Kaur R, Charan J, Bhardwaj P, Ambwani SR, Babu S, et al. Analysis of  
476 Neurological Adverse Events Reported in VigiBase From COVID-19 Vaccines. *Cureus*  
477 [Internet]. 2022 Jan;14(1):e21376. Available from: <http://dx.doi.org/10.7759/cureus.21376>
- 478 21. Montano D. Frequency and Associations of Adverse Reactions of COVID-19 Vaccines  
479 Reported to Pharmacovigilance Systems in the European Union and the United States.  
480 *Front Public Health* [Internet]. 2021;9:756633. Available from:  
481 <http://dx.doi.org/10.3389/fpubh.2021.756633>
- 482 22. Jeet Kaur R, Dutta S, Charan J, Bhardwaj P, Tandon A, Yadav D, et al. Cardiovascular  
483 Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database. *Int*  
484 *J Gen Med* [Internet]. 2021 Jul 27;14:3909–27. Available from:  
485 <http://dx.doi.org/10.2147/IJGM.S324349>
- 486 23. Centers for Disease Control and Prevention. Vaccine Adverse Event Reporting System  
487 (VAERS) Standard Operating Procedures for COVID-19 (as of 29 January 2021) [Internet].  
488 2021 Jan [cited 2022 Mar 30]. Available from:  
489 <https://www.cdc.gov/vaccinesafety/pdf/VAERS-v2-SOP.pdf>
- 490 24. Centers for Disease Control and Prevention. Vaccine safety publications [Internet]. 2022  
491 [cited 2022 Mar 31]. Available from:  
492 <https://www.cdc.gov/vaccinesafety/research/publications/index.html>
- 493 25. Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi SV, Razvi S, et al. Neurological  
494 complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. *Nat Med*  
495 [Internet]. 2021 Dec;27(12):2144–53. Available from: [http://dx.doi.org/10.1038/s41591-021-](http://dx.doi.org/10.1038/s41591-021-01556-7)  
496 [01556-7](http://dx.doi.org/10.1038/s41591-021-01556-7)
- 497 26. Jabagi MJ, Botton J, Bertrand M, Weill A, Farrington P, Zureik M, et al. Myocardial  
498 Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in  
499 People Aged 75 Years or Older. *JAMA* [Internet]. 2022 Jan 4;327(1):80–2. Available from:

- 500 <http://dx.doi.org/10.1001/jama.2021.21699>
- 501 27. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the  
502 BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. *N Engl J Med* [Internet]. 2021  
503 Sep 16;385(12):1078–90. Available from: <http://dx.doi.org/10.1056/NEJMoa2110475>
- 504 28. Benn CS, Schaltz-Buchholzer F, Nielsen S, Netea MG, Aaby P. Randomised Clinical Trials  
505 of COVID-19 Vaccines: Do Adenovirus-Vector Vaccines Have Beneficial Non-Specific  
506 Effects? [Internet]. 2022 [cited 2022 May 9]. Available from:  
507 <https://papers.ssrn.com/abstract=4072489>
- 508 29. Hampton LM, Aggarwal R, Evans SJW, Law B. General determination of causation  
509 between Covid-19 vaccines and possible adverse events. *Vaccine* [Internet]. 2021 Mar  
510 5;39(10):1478–80. Available from: <http://dx.doi.org/10.1016/j.vaccine.2021.01.057>
- 511 30. Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, et al. Characterising the  
512 background incidence rates of adverse events of special interest for covid-19 vaccines in  
513 eight countries: multinational network cohort study. *BMJ* [Internet]. 2021 Jun 14 [cited 2022  
514 Mar 28];373. Available from: <https://www.bmj.com/content/373/bmj.n1435>
- 515 31. Greenland S. Relation of probability of causation to relative risk and doubling dose: a  
516 methodologic error that has become a social problem. *Am J Public Health* [Internet]. 1999  
517 Aug;89(8):1166–9. Available from: <http://dx.doi.org/10.2105/ajph.89.8.1166>
- 518 32. MacLehose RF, Ahern TP, Lash TL, Poole C, Greenland S. The Importance of Making  
519 Assumptions in Bias Analysis. *Epidemiology* [Internet]. 2021 Sep 1;32(5):617–24. Available  
520 from: <http://dx.doi.org/10.1097/EDE.0000000000001381>
- 521 33. Greenland S. Invited Commentary: Dealing With the Inevitable Deficiencies of Bias  
522 Analysis-and All Analyses. *Am J Epidemiol* [Internet]. 2021 Aug 1;190(8):1617–21.  
523 Available from: <http://dx.doi.org/10.1093/aje/kwab069>
- 524 34. Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? *BMJ*  
525 [Internet]. 2007 Jan 20;334(7585):120–3. Available from:  
526 <http://dx.doi.org/10.1136/bmj.39024.487720.68>
- 527 35. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death  
528 from cardiovascular causes. *N Engl J Med* [Internet]. 2007 Jun 14;356(24):2457–71.  
529 Available from: <http://dx.doi.org/10.1056/NEJMoa072761>
- 530 36. Tanveer S, Rowhani-Farid A, Hong K, Jefferson T, Doshi P. Transparency of COVID-19  
531 vaccine trials: decisions without data. *BMJ Evid Based Med* [Internet]. 2021 Aug 9;  
532 Available from: <http://dx.doi.org/10.1136/bmjebm-2021-111735>
- 533 37. Doshi P, Godlee F, Abbasi K. Covid-19 vaccines and treatments: we must have raw data,  
534 now. *BMJ* [Internet]. 2022 Jan 19;376:o102. Available from:  
535 <http://dx.doi.org/10.1136/bmj.o102>
- 536  
537



<b>Table 1. Data sources for phase III trials</b>				
<b>Trial</b>	<b>Data cutoff date</b>	<b>Journal articles</b>	<b>FDA sources</b>	<b>Health Canada sources</b>
Pfizer trial in ages 16 and above ( <a href="#">NCT04368728</a> )	14 Nov 2020 (supported Dec 2020 EUA)	<a href="#">Aggregate data only</a>	<b>Table 23</b> in sponsor briefing document	<b>Table 55</b> in sponsor document C4591001 Final Analysis Interim Report Body
Moderna trial in ages 18 and above ( <a href="#">NCT04470427</a> )	25 Nov 2020 (supported Dec 2020 EUA)	<a href="#">Table S11</a> in publication	<a href="#">Table 27</a> in sponsor briefing document	<b>Table 14.3.1.13.3</b> in sponsor document mRNA-1273-P301 Unblinded Safety Tables Batch 1 (DS2)
Note: bolded font indicates dataset chosen for analysis; EUA = Emergency Use Authorization				

538  
539

<b>Table 2. Serious adverse events</b>				
	<b>Events<sup>a</sup></b>		<b>Risk difference per 10,000 participants (95% CI)</b>	<b>Risk ratio (95% CI)</b>
<b>Trial</b>	<b>Vaccine</b>	<b>Placebo</b>		
<b>All serious adverse events<sup>b</sup></b>				
Pfizer	127	93	18.0 (1.2 to 34.9)	1.36 (1.02 to 1.83)
Moderna	206	196	6.4 (-23.9 to 36.8)	1.05 (0.83 to 1.32)
Combined	333	289	12.9 (-0.4 to 29.3)	1.15 (0.96 to 1.38)
<b>Serious adverse events of special interest<sup>c</sup></b>				
Pfizer	52	33	10.1 (-0.4 to 20.6)	1.57 (0.98 to 2.54)
Moderna	87	64	15.1 (-3.6 to 33.8)	1.36 (0.93 to 1.99)
Combined	139	97	12.5 (2.1 to 22.9)	1.43 (1.07 to 1.92)
<p><sup>a</sup> Denominators for Pfizer were 18,801 in the vaccine group and 18,785 in the placebo group, and for Moderna were 15,185 in the vaccine group and 15,166 in the placebo group.</p> <p><sup>b</sup> All SAEs are included in the calculations except for efficacy outcomes which were included in certain SAE tables: "COVID-19" and "COVID-19 pneumonia" (Moderna) and "SARS-CoV-2 test positive" (Pfizer). "All SAEs" for Moderna was calculated using the "Number of serious AEs" row in Moderna's submission to FDA.<sup>10</sup></p> <p><sup>c</sup> Standard errors used to estimate 95% CIs were inflated by the factor <math>\sqrt{[\#SAE]/[\#patients\ with\ SAE]}</math> to account for multiple SAE within patients.</p>				

541

542

543

544



**Table 3. Serious AEs, Pfizer trial**

<i>Brighton category</i>	Vaccine	Placebo	Vaccine events per 10,000	Placebo events per 10,000	Difference in events per 10,000	Risk ratio
<b>Association with immunization in general</b>						
Anaphylaxis	1	1	0.5	0.5	0.0	1.00
<b>Association with specific vaccine platform(s)</b>						
Encephalitis/encephalomyelitis	0	2	0.0	1.1	-1.1	0.00
<b>Seen with COVID-19</b>						
Acute kidney injury	2	0	1.1	0.0	1.1	N/A
Acute liver injury	0	1	0.0	0.5	-0.5	0.00
Acute respiratory distress syndrome	2	1	1.1	0.5	0.5	2.00
Coagulation disorder	16	10	8.5	5.3	3.2	1.60
Myocarditis/pericarditis	2	1	1.1	0.5	0.5	2.00
Other forms of acute cardiac injury	16	12	8.5	6.4	2.1	1.33
Subtotal	39	28	20.7	14.9	5.8	1.39
<b>Brighton list of 29 clinical diagnoses seen with COVID-19</b>						
Abscess	4	1	2.1	0.5	1.6	4.00
Cholecystitis	4	2	2.1	1.1	1.1	2.00
Colitis/Enteritis	1	1	0.5	0.5	0.0	1.00
Diarrhea	1	0	0.5	0.0	0.5	N/A
Hyperglycemia	1	1	0.5	0.5	0.0	1.00
Pancreatitis	1	0	0.5	0.0	0.5	N/A
Psychosis	1	0	0.5	0.0	0.5	N/A
Subtotal	13	5	6.9	2.7	4.3	2.60
<b>Total</b>	<b>52</b>	<b>33</b>	<b>27.7</b>	<b>17.6</b>	<b>10.1</b>	<b>1.57</b>

**Table 4. Serious AESIs, Moderna trial**

<i>Brighton category</i>	Vaccine	Placebo	Vaccine events per 10,000	Placebo events per 10,000	Difference in events per 10,000	Risk ratio
<b>Association with specific vaccine platform(s)</b>						
Bell's Palsy	1	0	0.7	0.0	0.7	N/A
Encephalitis/encephalomyelitis	1	0	0.7	0.0	0.7	N/A
<b>Seen with COVID-19</b>						
Acute kidney injury	1	3	0.7	2.0	-1.3	0.33
Acute liver injury	1	0	0.7	0.0	0.7	N/A
Acute respiratory distress syndrome	7	4	4.6	2.6	2.0	1.75
Angioedema	0	2	0.0	1.3	-1.3	0.00
Coagulation disorder	20	13	13.2	8.6	4.6	1.54
Generalized Convulsions	2	0	1.3	0.0	1.3	N/A
Myelitis	0	1	0.0	0.7	-0.7	0.00
Myocarditis/pericarditis	4	5	2.6	3.3	-0.7	0.80
Other forms of acute cardiac injury	26	26	17.1	17.1	0.0	1.00
Other rash	1	1	0.7	0.7	0.0	1.00
Rhabdomyolysis	0	1	0.0	0.7	-0.7	0.00
Single Organ Cutaneous Vasculitis	1	0	0.7	0.0	0.7	N/A
Subtotal	65	56	42.8	36.9	5.9	1.16
<b>Brighton list of 29 clinical diagnoses seen with COVID-19</b>						
Abscess	1	0	0.7	0.0	0.7	N/A
Arthritis	3	1	2.0	0.7	1.3	3.00
Cholecystitis	4	0	2.6	0.0	2.6	N/A
Colitis/Enteritis	6	3	4.0	2.0	2.0	2.00

Diarrhea	2	1	1.3	0.7	0.7	2.00
Hyperglycemia	1	0	0.7	0.0	0.7	N/A
Hyponatremia	1	1	0.7	0.7	0.0	1.00
Pancreatitis	2	0	1.3	0.0	1.3	N/A
Pneumothorax	0	1	0.0	0.7	-0.7	0.00
Psychosis	1	1	0.7	0.7	0.0	1.00
Thyroiditis	1	0	0.7	0.0	0.7	N/A
Subtotal	22	8	14.5	5.3	9.2	2.75
<b>Total</b>	<b>87</b>	<b>64</b>	<b>57.3</b>	<b>42.2</b>	<b>15.1</b>	<b>1.36</b>

### Supplemental Table 1. Included and excluded SAE types across both trials

**Included SAE types (matching AESI list):** Abdominal pain, Abdominal pain upper, Abscess, Abscess intestinal, Acute coronary syndrome, Acute kidney injury, Acute left ventricular failure, Acute myocardial infarction, Acute respiratory failure, Anaemia, Anaphylactic reaction, Anaphylactic shock, Angina pectoris, Angina unstable, Angioedema, Aortic aneurysm, Aortic valve incompetence, Arrhythmia supraventricular, Arteriospasm coronary, Arthritis, Atrial fibrillation, Atrial flutter, Axillary vein thrombosis, Basal ganglia haemorrhage, Bile duct stone, Blood loss anaemia, Bradycardia, Brain abscess, Cardiac failure, Cardiac failure acute, Cardiac failure congestive, Cardiac stress test abnormal, Cardio-respiratory arrest, Cerebral infarction, Cerebrovascular accident, Chest pain, Cholecystitis, Cholecystitis acute, Cholelithiasis, Colitis, Coronary artery disease, Coronary artery dissection, Coronary artery occlusion, Coronary artery thrombosis, Deep vein thrombosis, Dermatitis bullous, Diabetic ketoacidosis, Diarrhoea, Diplegia, Dyspnoea, Embolic stroke, Empyema, Facial paralysis, Fluid retention, Gastroenteritis, Gastrointestinal haemorrhage, Haematoma, Haemorrhagic stroke, Hemiplegic migraine, Hepatic enzyme increased, Hyperglycaemia, Hyponatraemia, Hypoxia, Ischaemic stroke, Laryngeal oedema, Multiple sclerosis, Myocardial infarction, Non-cardiac chest pain, Oedema peripheral, Pancreatitis, Pancreatitis acute, Pericarditis, Peripheral artery aneurysm, Peritoneal abscess, Pleuritic pain, Pneumothorax, Post procedural haematoma, Post procedural haemorrhage, Postoperative abscess, Procedural haemorrhage, Psychotic disorder, Pulmonary embolism, Rash, Rash vesicular, Respiratory failure, Retinal artery occlusion, Rhabdomyolysis, Rheumatoid arthritis, Schizoaffective disorder, Seizure, Subarachnoid haemorrhage, Subcapsular renal haematoma, Subdural haematoma, Tachyarrhythmia, Tachycardia, Thrombocytopenia, Thyroid disorder, Toxic encephalopathy, Transaminases increased, Transient ischaemic attack, Traumatic intracranial haemorrhage, Type 2 diabetes mellitus, Uraemic encephalopathy, Uterine haemorrhage, Vascular stent occlusion, Ventricular arrhythmia

**Excluded SAE types (not matching AESI list):** Abdominal adhesions, Abortion spontaneous, Abortion spontaneous incomplete, Accelerated hypertension, Adenocarcinoma gastric, Adrenal gland cancer, Alcohol abuse, Alcohol poisoning, Alcohol withdrawal syndrome, Animal bite, Ankle arthroplasty, Ankle fracture, Anxiety, Anxiety disorder, Aortic stenosis, Appendicitis, Appendicitis perforated, Arteriosclerosis, Asthma, Atelectasis, Autonomic nervous system imbalance, B-cell small lymphocytic lymphoma, Back injury, Back pain, Benign prostatic hyperplasia, Bipolar disorder, Breast cancer, Breast cancer stage I, Breast hyperplasia, Bronchitis, Cartilage injury, Cellulitis, Cervical radiculopathy, Cervical spinal stenosis, Cervical vertebral fracture, Choroidal neovascularisation, Chronic kidney disease, Chronic lymphocytic leukaemia, Chronic myeloid leukaemia, Chronic obstructive pulmonary disease, Clostridium difficile colitis, Clostridium difficile infection, Colon cancer stage III, Colon injury, Colorectal cancer, Completed suicide, Complicated appendicitis, Concussion, Confusional state, Constipation, Cough, Craniocerebral injury, Dehydration, Depression, Diplopia, Diverticular perforation, Diverticulitis, Dizziness, Drug hypersensitivity, Duodenal ulcer, Duodenal ulcer haemorrhage, Emphysema, Facial bones fracture, Fall, Feeling hot, Femoral neck fracture, Femur fracture, Fibromuscular dysplasia, Flail chest, Flank pain, Food poisoning, Foot fracture, Foot operation, Forearm fracture, Fracture nonunion, Gastric cancer, Gastric perforation, Gastrooesophageal reflux disease, Gout, Gun shot wound, Head injury, Heart disease congenital, Hepatic cancer metastatic, Hepatic mass, Hepatitis A, Hernia, Hiatus hernia, Hip arthroplasty, Hip fracture, Humerus fracture, Hypertension, Hypertensive emergency, Hypertensive urgency, Hypoglycaemia,

Hypokalaemia, Hypomagnesaemia, Hypotension, Idiopathic intracranial hypertension, Immunisation anxiety related reaction, Incarcerated hernia, Incision site pain, Influenza like illness, Intentional self-injury, Interstitial lung disease, Intervertebral disc degeneration, Intervertebral disc protrusion, Intestinal obstruction, Intestinal perforation, Intraductal proliferative breast lesion, Invasive ductal breast carcinoma, Invasive lobular breast carcinoma, JAMMED RIGHT INGUINAL HERNIA@@, Jaw operation, Joint injury, Knee arthroplasty, Large intestine perforation, Lead dislodgement, Leiomyosarcoma metastatic, Leydig cell tumour of the testis, Ligament rupture, Loss of consciousness, Lower limb fracture, Lung cancer metastatic, Lymphadenopathy, Major depression, Malignant melanoma, Meningioma, Mental disorder, Metabolic acidosis, Metastases to central nervous system, Migraine, Multiple injuries, Musculoskeletal chest pain, Nausea, Neck pain, Nephrolithiasis, Neutropenia, Obstructive pancreatitis, Oesophageal carcinoma, Oesophageal food impaction, Organising pneumonia, Orthostatic hypotension, Osteoarthritis, Osteochondritis, Osteomyelitis, Ovarian cyst, Ovarian mass, Overdose, Pancreatic mass, Papillary thyroid cancer, Paraesthesia, Pelvic neoplasm, Penile cancer, Penile neoplasm, Peritonitis, Pharyngitis streptococcal, Pleural effusion, Pneumonia, Pneumonia aspiration, Pneumonia staphylococcal, Pneumonitis, Polymyalgia rheumatica, Postoperative wound infection, Precancerous condition, Prostate cancer, Prostate cancer metastatic, Pulmonary mass, Pyelonephritis, Pyelonephritis acute, Rectal prolapse, Renal cancer, Renal cell carcinoma, Renal colic, Retinal detachment, Retinal tear, Rib fracture, Road traffic accident, Salivary gland calculus, Salpingitis, Sepsis, Septic shock, Sexual abuse, Shoulder injury related to vaccine administration, Skin laceration, Small intestinal obstruction, Speech disorder, Spinal cord injury cervical, Spinal fusion surgery, Spinal stenosis, Staphylococcal infection, Streptococcal sepsis, Suicidal ideation, Suicide attempt, Suspected COVID-19, Swelling face, Syncope, Systemic inflammatory response syndrome, Tendon rupture, Thoracic vertebral fracture, Thyroidectomy, Toxic shock syndrome, Toxicity to various agents, Transient global amnesia, Traumatic liver injury, Ulna fracture, Umbilical hernia, Unevaluable event, Urinary bladder polyp, Urinary tract infection, Urosepsis, Uterine leiomyoma, Uterine prolapse, Vertigo, Viral pharyngitis, Volvulus, Vomiting, Wound infection, Wrist fracture

**Excluded SAE types (efficacy-related endpoints):** COVID-19, COVID-19 pneumonia, SARS-CoV-2 test positive.

Note: Pfizer and Moderna coded all SAEs using the MedDRA coding dictionary; terms here are reproduced verbatim from the SAE tables. Preferred terms with @@ denote uncoded terms.

<b>Supplemental Table 2. Sensitivity analysis</b>				
	<b>Events<sup>a</sup></b>		<b>Risk difference per 10,000 participants (95% CI)</b>	<b>Risk ratio (95% CI)</b>
<b>Trial</b>	<b>Vaccine</b>	<b>Placebo</b>		
<b>Serious adverse events of special interest<sup>b</sup></b>				
Pfizer	52	33	10.1 (-0.4 to 20.6)	1.57 (0.98 to 2.54)
Moderna	87	64	15.1 (-3.6 to 33.8)	1.36 (0.93 to 1.99)
Combined	139	97	12.5 (2.1 to 22.9)	1.43 (1.07 to 1.92)
<b>SAEs matching Brighton's SPEAC COVID-19 AESI list<sup>c,d</sup></b>				
Pfizer	39	28	5.8 (-3.5 to 15.2)	1.39 (0.82 to 2.37)
Moderna	65	56	5.9 (-10.9 to 22.6)	1.16 (0.76 to 1.77)
Combined	104	84	5.9 (-3.2 to 15.0)	1.24 (0.89 to 1.72)
<p><sup>a</sup> Denominators for Pfizer were 18,801 in the vaccine group and 18,785 in the placebo group, and for Moderna were 15,185 in the vaccine group and 15,166 in the placebo group.</p> <p><sup>b</sup> This analysis, presented in the main paper, is reproduced here for ease of interpreting the sensitivity analysis.</p> <p><sup>c</sup> This list does not include the 29 clinical diagnoses Brighton identified as "known to have been reported [in conjunction with COVID-19] but not in sufficient numbers to merit inclusion on the AESI list."</p> <p><sup>d</sup> Standard errors used to estimate 95% CIs were inflated by the factor <math>\sqrt{[\#SAE]/[\#patients\ with\ SAE]}</math> to account for multiple SAE within patients.</p>				